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Abstract
Background: The use of artemisinin-based combination therapy (ACT) at the community level
has been advocated as a means to increase access to effective antimalarial medicines by high risk
groups living in underserved areas, mainly in sub-Saharan Africa. This strategy has been shown to
be feasible and acceptable to the community. However, the parasitological effectiveness of ACT
when dispensed by community medicine distributors (CMDs) within the context of home
management of malaria (HMM) and used unsupervised by caregivers at home has not been
evaluated.
Methods: In a sub-set of villages participating in a large-scale study on feasibility and acceptability
of ACT use in areas of high malaria transmission in Ghana, Nigeria and Uganda, thick blood smears
and blood spotted filter paper were prepared from finger prick blood samples collected from
febrile children between six and 59 months of age reporting to trained CMDs for microscopy and
PCR analysis. Presumptive antimalarial treatment with ACT (artesunate-amodiaquine in Ghana,
artemether-lumefantrine in Nigeria and Uganda) was then initiated. Repeat finger prick blood
samples were obtained 28 days later for children who were parasitaemic at baseline. For children
who were parasitaemic at follow-up, PCR analyses were undertaken to distinguish recrudescence
from re-infection. The extent to which ACTs had been correctly administered was assessed
through separate household interviews with caregivers having had a child with fever in the previous
two weeks.
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Results: Over a period of 12 months, a total of 1,740 children presenting with fever were enrolled
across the study sites. Patent parasitaemia at baseline was present in 1,189 children (68.3%) and
varied from 60.1% in Uganda to 71.1% in Ghana. A total of 606 children (51% of infected children)
reported for a repeat test 28 days after treatment. The crude parasitological failure rate varied
from 3.7% in Uganda (C.I. 1.2%–6.2%) to 41.8% in Nigeria (C.I. 35%–49%). The PCR adjusted
parasitological cure rate was greater than 90% in all sites, varying from 90.9% in Nigeria (C.I. 86%–
95%) to 97.2% in Uganda (C.I. 95%–99%). Reported adherence to correct treatment in terms of
dose and duration varied from 81% in Uganda (C.I. 67%–95%) to 97% in Ghana (C.I. 95%–99%) with
an average of 94% (C.I. 91%–97%).
Conclusion: While follow-up rates were low, this study provides encouraging data on
parasitological outcomes of children treated with ACT in the context of HMM and adds to the
evidence base for HMM as a public health strategy as well as for scaling-up implementation of HMM
with ACTs.
Background
Artemisinin-based combination therapy (ACT) is cur-
rently the universally recommended first-line therapy for
uncomplicated malaria [1]. Numerous trials have shown
ACT to be highly efficacious when used under controlled
conditions [2-4], and some studies have confirmed their
efficacy when used under partially supervised conditions
[5,6].
The use of ACT at the community level has been advo-
cated as a means to increase access to effective antimalar-
ial medicines by high risk groups living in underserved
areas, mainly in sub-Saharan Africa [1,7,8]. This strategy,
known as Home Management of Malaria (HMM), has
been shown to be feasible and acceptable to the commu-
nity [9-14]. However, while wide deployment of ACT at
the community level through HMM has the potential to
greatly reduce malaria related mortality and severe mor-
bidity, such implementation has until now been delayed
by substantial economic and public health issues. These
include concerns about the effective use of ACT at the
community level [15], as the parasitological cure rate that
is achieved with ACT in the context of HMM, when dis-
pensed by community medicine distributors (CMDs) and
used unsupervised by caregivers at home, has not been
assessed.
In addition, poor adherence to the treatment schedule by
both caregivers and CMDs, or a failure to provide ade-
quate storage conditions to ensure drug stability in the
community could reduce the efficacy of ACT and facilitate
the emergence of drug resistance. There is thus a need for
research to provide the evidence base to accompany
deployment of ACT beyond the health facility level
[16,17] including documenting the actual cure rate that
can be obtained by ACT deployed within the context of
HMM programmes.
To provide additional evidence to support the use of ACT
at the community level, the UNICEF-UNDP-WORLD
BANK-WHO Special Programme for Research and Train-
ing in Tropical Diseases (TDR) funded studies in Ghana,
Nigeria and Uganda, representing different health systems
and epidemiological settings. Report on the feasibility
and acceptability of incorporating ACT in HMM has been
published [18]. In this paper the parasitological cure rates
achieved by ACT provided at the community level within
the context of HMM programmes in the same study sites
are reported.
Methods
A multi-centre study of the use of ACT within the context
of HMM in three African countries was carried out. Details
of the study sites and the implementation of HMM in
those sites have been previously reported [18].
Study sites
Three sites participated in the evaluation of parasitologi-
cal cure rates: Ejisu-Juaben district in Ghana, Badeku and
Ojoku/Ajia districts in Nigeria, and Bugiri district in
Uganda. All three sites are rural areas in which malaria is
hyper-endemic, with perennial transmission accompa-
nied by seasonal peaks. The entomological inoculation
rate (EIR) is estimated to be of the order of 500 infective
bites per person per year in Ejisu-Juaben district [19] and
Badeku and Ojoku/Ajia districts [20]. The EIR is not
known for Bugiri district in Uganda, but is reported to be
500 infective bites per person per year or more in the
neighbouring district of Tororo [21], which has similar
ecology. In each site, a sub-sample of all villages partici-
pating in the study was selected for the study of ACT effec-
tiveness, based on accessibility during the rainy season
and logistics: 9/36 villages in Ghana, 7/40 in Nigeria and
3/37 in Uganda.
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Study design
The study involved follow-up of children between six to
59 months of age, whose caregivers reported to CMDs
with a complaint of fever. The CMDs in the study areas
had been trained on the signs and symptoms of both
severe and uncomplicated malaria, to educate caregivers
on the use of ACTs, on the preparation of thin and thick
blood films and blood spots on filter paper as well as on
proper storage of the specimens (filter papers and stained
blood smear slides).
Study implementation
At the time of the first visit of the febrile child and after
informed consent had been obtained from the caregiver ,
CMDs prepared blood slides for microscopy and collected
blood on filter paper [3 mm Whatman] for PCR analysis.
In line with the currently recommended HMM strategy
[8]), antimalarial treatment with ACT was then given
based on clinical grounds. Children with signs of severe
disease were excluded from the study and immediately
referred to the nearest health centre. In Ghana and Nigeria
antimalarial drugs were given to caregivers accompanied
by instructions, following which caregivers treated their
children at home unsupervised. In Uganda, the first dose
was administered to the child in the presence of the CMD,
while subsequent doses were administered unsupervised,
although the CMDs were expected to make home visits to
remind the mothers to give the treatment on subsequent
days. All caregivers were instructed to report to the CMDs
or the nearest health facility if the child had not improved
after 48 hours or if the child deteriorated at any time.
Blood slides were read daily in local research laboratories
and results returned to the CMDs the next day. Thereafter,
CMDs provided the result to the mothers/caregivers.
Mothers/caregivers of children with microscopically con-
firmed malaria were instructed to return for follow-up on
day 28. On day 28 the caregivers were asked about symp-
toms and repeat peripheral blood films and blood spots
on filter paper were obtained from their children. Caregiv-
ers of children who were free of patent parasitaemia were
advised to take their children to the health centre or any
health facility of their choice.
Study drugs
In accordance with the national drug policies of the par-
ticipating countries, a fixed combination of 20 mg of arte-
mether and 120 mg of lumefantrine (AL) was used in
Uganda and Nigeria, and a loose combination of artesu-
nate and amodiaquine (AS/AQ) was used in Ghana. The
recommended dose for AL in children between six and 35
months of age was one tablet twice daily for three days,
and two tablets twice daily for three days in children
between 36 and 59 months of age. Caregivers were
advised to administer the drug after meals, preferably fatty
food. For the AS/AQ combination, blister packs contain-
ing co-packed artesunate and amodiaquine tablets of 50
and 153 mgs respectively were used. For children aged 12
to 59 months the recommended dose of AS/AQ was one
tablet of each drug once per day. However, for children
aged 6 to 11 months, tablets had to be broken in half and
repackaged to comply with the recommended AS/AQ
dose in that age group. In all countries, antimalarial med-
icines for the study were provided by the Ministry of
Health free of charge.
Training
Recruitment and training of field supervisors
A two-day training workshop was organized for the field
supervisors to acquaint them with the intervention activi-
ties and the data collection tools. They were trained on
how to make slides, blood spots on filter paper for PCR
analysis and on proper storage of the specimens (filter
papers and stained blood smear slides) in order to ade-
quately supervise the CMDs. The mechanisms of drug dis-
tribution and supervision were also discussed.
Recruitment and training of the community based medicine 
distributors
A total of 47 CMDs were recruited (17 in Ghana, 24 in
Nigeria and 6 in Uganda), following selection by the
respective communities. A three-day workshop (two days
of demonstration followed by a one day field practical)
was held for the CMDs in each study site. The training cov-
ered the clinical features of malaria, diagnosis, prepara-
tion of blood smears on slides, spotting blood on filter
paper and treatment including dosage regimen. The
CMDs were also instructed on the administration of con-
sent forms, filling of data collection forms and criteria for
referral. Refresher training on slide and filter paper prepa-
ration was performed during supervision by the field staff
in the first month after initial training.
Caregivers' compliance and CMDs' correctness of prescription
Adherence to prescribed treatment schedules was assessed
through cross-sectional surveys involving household
interviews with caregivers of children with fever in the pre-
vious two weeks. All households in the study communi-
ties were visited and caregivers who met the inclusion
criteria [has a child aged 6–59 months with fever in the
two weeks preceding survey and have been resident in the
community for at least six months] were interviewed. In
cases were more than one caregiver in a household met
the inclusion criteria, balloting was carried out to select
the one to interview. During the interview, caregivers were
questioned about the timing of treatment, the number of
doses administered and the number of days over which
drug was given. Used packs of drugs were inspected where
available. The correctness of prescription by the CMDs
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was assessed by inspection of CMDs' registers during
supervisory visits.
Laboratory procedures
Microscopy
Thick blood films and Whatman filter papers with blood
spots prepared by CMDs from finger prick blood samples
were collected from the CMDs within 24 hours. Blood
films were stained with 10% Giemsa stain for 30 minutes
and screened microscopically under X100 oil immersion
lens using a light microscope. Intensity of infection was
estimated by counting the number of asexual parasites in
relation to 200 white blood cells. Parasite density was cal-
culated assuming a mean leukocyte count of 8,000/μl
blood. Ten percent of the slides were selected at random
and re-read by an independent microscopist at each cen-
tre. Disagreements in readings were found in less than 5%
of cases in all sites.
DNA extraction and PCR amplification
Molecular genotyping for all sites was performed in
Ibadan, Nigeria. Parasite genomic DNA was extracted
from filter paper blood spots using the chelex extraction
method [22]. Genotyping of parasite populations was per-
formed for all samples collected from patients with micro-
scopically confirmed Plasmodium falciparum infections at
enrollment and who were parasitaemic at day 28 follow-
up. Three highly polymorphic loci (block 1 of merozoite
surface protein 1 (msp1), block 3 of merozoite surface pro-
tein 2 (msp2) and region II of glutamate rich protein
(glurp)) of P. falciparum were amplified by nested PCR
using oligonucleotide primers, reaction conditions and
procedures described previously [22]. Ten microliters of
each of the nested PCR products was resolved by electro-
phoresis on a 2% agarose gel stained with ethidium bro-
mide and sized against a 100-base pair molecular weight
marker (New England Biolabs, Beverly, MA).
Each P. falciparum infection was characterized on the basis
of fragment sizes of PCR products for each locus. If an iso-
late had just one allele at each of the three loci, the clone
number was taken to be one. Infections were defined as
polyclonal if more than one allele from one or more genes
was apparent, as previously described [23] and currently
recommended by the WHO/MMV informal consultation
on methods and techniques for genotyping to identify
parasite population [24]. Briefly, recrudescent infections
were defined as the occurrence of the same or a subset of
alleles at all three loci (msp-1, msp-2 and glurp) in pre- and
post-treatment samples. A lack of allelic identity at any of
the three loci in pre- and post-treatment samples was con-
sidered to indicate a newly acquired infection/re-infec-
tion. An "unresolved" result was recorded when the
parasite DNA could not be amplified. These samples were
excluded from the analysis.
Data analysis
Data were entered onto microcomputer and analysed
using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) and
STATA 9.0 (Stata Corp., Texas, USA 2005)
Ethical clearance
The study was approved by the Ethics Review Committees
in all participating countries and at the World Health
Organization (WHO).
Results
Parasite prevalence and cure rate
Over a period of 12 months, a total of 1740 children pre-
senting with fever were enrolled across the study sites. Of
these, 1,189 (68.3%) had patent parasitaemia prior to
treatment, of whom 606 (51%) reported for follow-up 28
days after treatment. The prevalence of parasitaemia prior
to treatment was lower in Uganda than in Nigeria and
Ghana (61% vs. 71% and 71% respectively, p < 0.001).
The proportion of children followed up at Day 28 was
lowest in Ghana (34%) compared with 60% in Nigeria
and 78% in Uganda. The crude parasitological failure rate
was 41.8% in Nigeria (C.I. 35%–49%), 27.8% in Ghana
(C.I. 22%–34%) and 3.7% in Uganda (C.I. 1.2%–6.2%).
The PCR adjusted cure rate was over 90% in all sites, rang-
ing from 91% in Nigeria and Ghana (C.I. 86%–95% and
87%–95% respectively) to 97% in Uganda (C.I. 95%–
99%) (Table 1).
Adherence
Adherence by caregivers to the correct treatment was
assessed in 244 febrile children across the three study
sites. Adherence was measured in terms of caregiver's
report of the number of doses administered to the child,
the number of days over which the treatment was given
and the promptness of treatment after onset of symptoms.
Overall, 94% (C.I. 91%–97%) of children were treated
correctly in terms of drug dose and duration of adminis-
tration. The level of adherence was lower in Uganda
(81%, C.I. 67%–95%) compared to Nigeria (93%, C.I.
87%–99%) and Ghana (97%, C.I. 95%–99%) (Table 2).
Discussion
The study provides two important new pieces of informa-
tion. Firstly, it quantifies the prevalence of malaria infec-
tion among children seeking treatment from CMDs
because of fever of suspected malaria origin in three areas
of high malaria transmission. In all study sites (all rural,
with EIRs of the order of 500) malaria prevalence
exceeded 50%, ranging from 61% to 71%. This finding
has important implications for policy at local level, as the
usefulness and cost-effectiveness of rapid diagnostic tests
(RDT) for malaria may vary with the intensity of transmis-
sion [25] and with the parasitaemia prevalence level [26].
The proportion of children with parasitaemia in this study
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is higher than that of 42% reported in Tanzania in a pop-
ulation of febrile children seeking treatment from drug
stores or health facilities [27]. However, the Tanzania
study did not report the EIR in that area.
Secondly, it provides the first data on the cure rate that can
be obtained with the use of ACT prescribed by CMDs and
administered unsupervised by caregivers at home, a strat-
egy that is advocated to improve access to effective treat-
ment by underserved communities living in sub-Saharan
Africa. The PCR adjusted cure rate varied among the sites
from 91% in Nigeria to 97% in Uganda, rates which are
all above the threshold of 90% below which WHO recom-
mends changing antimalarial drug policy [28]. However,
the failure rates recorded in the Nigeria and Ghana sites
(9.1% and 8.6% respectively) are higher than those
reported in controlled AL and AS/AQ efficacy studies (<
5%) [4,29], while that recorded for Uganda (2.8%) is con-
sistent with reports in literature. The study also shows that
at Day 28, the majority of infections that can be detected
by microscopy after treatment with AL or AS/AQ are due
to re-infections with new strains of P. falciparum, a finding
that had already been reported in literature [23].
Incomplete adherence by caregivers to the correct dosage
and treatment regimen when unsupervised, has been sug-
gested as a possible cause of decreased effectiveness of
ACT [30,31] and a concern with regard to HMM with ACT
[15]. While some studies failed to find a difference in cure
rate between ACT dispensed supervised and unsupervised
[5,6], others have reported a significant difference in ther-
apeutic response after supervised and unsupervised treat-
ment that can only be explained by insufficient patient
adherence [30].
This seems an unlikely explanation in this study. Reported
adherence by caregivers was consistently high (over 80%)
across sites. However, adherence was assessed based on
caregivers' recall only and the possibility that some car-
egivers did not report adherence accurately should be
borne in mind. Day 7 plasma lumefantrine level has been
reported to be a useful predictor of the bioavailability and
compliance with the artemether lumefantrine co-formula-
tion [31,32]. Thus, measurement of drug plasma levels
may offer a more reliable method of measuring adherence
than recall but is more invasive and more costly.
Higher crude parasitological failure rates were observed in
Nigeria and Ghana compared to Uganda, despite the
former areas reporting higher proportions of correctly
treated children than the latter. Although the rate of recru-
descence was drastically reduced in both Nigeria and
Table 1: Treatment outcome of AL and AS/AQ at D28.
Study site Drug used Enrolled Parasitaemic 
patients on D0 
N (%)
Patients seen 
at D28 N (%)
Crude 
parasitological 
failure (%)
Geometric mean 
parasite density 
D28 (p/μl)
PCR adjusted 
failure rate*
PCR adjusted 
cure rate
Badeku & 
Ojoku/Ajia 
Nigeria
AL 432 306 (70.8%)
C.I. 67%–75%
184 (60.1%) 77/184 (41.8%)
C.I. 35%–49%
2835 14/154 (9.1%) 90.9%
C.I.
86%–95%
Ejisu-Juaben, 
Ghana
AS/AQ 848 603 (71.1%)
C.I. 68%–74%
205 (34%) 57/205 (27.8%)
C.I. 22%–34%
15080 17/197 (8.6%) 91.4%
C.I.
87%–95%
Bugiri, Uganda AL 460 280 (60.9%)
C.I. 56%–65%
217 (77.5%) 8/217 (3.7%)
C.I. 1.2%–6.2%
N/A 6/216 (2.8%) 97.2%
C.I.
95%–99%
*= Samples that could not be classified by PCR were excluded from the analysis
AL = artemether-lumefantrine
AS/AQ = artesunate-amodiaquine
Table 2: Adherence of caregivers to treatment schedule in terms of dose and duration. 
Ejisu – Juaben District, Ghana Badeku and Ojoku/Ajia districts, 
Nigeria
Bugiri District, Uganda Totals
Total number of febrile children 
identified
211 132 44 387
Number of febrile children treated 
with ACTs from a CMD
153 60 31 244
Number (%) of children correctly 
treated (dose and duration)
149 (97%)
C.I. 95%–99%
56 (93%)
C.I. 87% – 99%
25 (81%)
C.I. 67% – 95%
230 (94%)
C.I. 91% – 97%
(source: HH survey in effectiveness sites)
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Ghana after genotyping, the overall pattern remained
unchanged (Table 1). This pattern might be partly
explained by higher transmission intensity in Nigeria and
Ghana compared to Uganda, as suggested by higher base-
line parasite prevalence in Table 1. It should also be noted
that the frequency and distribution of msp1, msp2 and
glurp alleles used to correct the failure rate have not been
thoroughly investigated in the study areas. As in many
other studies [33-35], these alleles were used under the
assumption that they have similarly high levels of diver-
sity across the study sites. If there is little genetic diversity,
but high transmission intensity, new infections of the
same genotype will be common and erroneously classed
as recrudescence. Therefore, it is recommended that geno-
typing results in efficacy studies and clinical trials should
be interpreted with some caution [23].
In interpreting these results, it is important to consider
some limitations of the study methods. The protocol used
to determine the parasitological efficacy of ACT is simple,
with collection of blood samples done only at baseline
and after 28 days of treatment. This has limited the capac-
ity to detect the timing at which treatment failures
occurred and to analyse the relative contribution of recru-
descences and re-infections over time. Also, the follow-up
procedure of children with malaria positive microscopy at
baseline was mainly based on spontaneous reporting,
which may have introduced a selection bias in the group
of children that were tested at Day 28, with important var-
iations in the proportion of children reporting for follow
up across study sites. Finally, adherence was measured by
questionnaires administered to caregivers, providing
potential for recall bias, and no determination of lume-
fantrine blood levels was done. Most of these limitations
derive from the fact that the study was carried out as part
of a larger study to determine feasibility and acceptability
of ACT use within HMM, including caregiver adherence
and treatment coverage. In this context there was a need
to minimize interference with spontaneous behaviours
and real life conditions of use of antimalarials. A strict fol-
low up protocol would have influenced the behaviour of
the caregivers and thus limited the generalizability of the
findings of the main study.
The community effectiveness of antimalarial treatment is
known to be influenced by a variety of factors beyond par-
asitological efficacy. These include access to effective treat-
ment, quality of prescription and caregiver adherence
[18,36-38]. However, measuring the parasitological cure
rate that can be obtained using ACT in the context of
HMM is of fundamental importance, given the current
call for widespread use of ACT at community level to
move towards malaria elimination [7]. While further
studies, carried out under more controlled conditions, are
necessary to establish the cure rate of ACT with a higher
degree of precision, this study provides initial information
and reassurance with regard to the effectiveness of ACT
used at the community level under real life conditions of
use. In this sense, findings of this study provide further
evidence to support scaling-up implementation of HMM
with ACTs.
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